中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
9期
1326-1328
,共3页
糖尿病肾病%胰岛素抗体%吡咯列酮%瑞格列奈
糖尿病腎病%胰島素抗體%吡咯列酮%瑞格列奈
당뇨병신병%이도소항체%필각렬동%서격렬내
Diabetic nephropathy%Insulin antibodies%Pioglitazone%Repaglinide
目的 观察吡咯列酮联合瑞格列奈治疗外源性胰岛素抗体阳性的2型糖尿病肾病的疗效.方法 将44例外源性胰岛素抗体阳性的糖尿病肾病患者分成治疗组(22例)和对照组(22例),治疗组停用胰岛素改为吡咯列酮15 mg,每天1次,瑞格列奈1 mg,每天3次,口服并逐渐调正剂量,对照组胰岛素,共治疗12周,治疗前后测定血糖、血脂、糖化血红蛋白等.结果 2型糖尿病肾病患者经口服吡咯列酮联合瑞格列奈治疗后血糖、糖化血红蛋白、尿白蛋白与尿肌酐比值等较前均有显著降低(均P＜0.01),上述指标与对照组治疗后同期差异有统计学意义(P＜0.05).结论 吡咯列酮联合瑞格列奈应用是治疗外源性胰岛素抗体阳性的2型糖尿病肾病的有效方法.
目的 觀察吡咯列酮聯閤瑞格列奈治療外源性胰島素抗體暘性的2型糖尿病腎病的療效.方法 將44例外源性胰島素抗體暘性的糖尿病腎病患者分成治療組(22例)和對照組(22例),治療組停用胰島素改為吡咯列酮15 mg,每天1次,瑞格列奈1 mg,每天3次,口服併逐漸調正劑量,對照組胰島素,共治療12週,治療前後測定血糖、血脂、糖化血紅蛋白等.結果 2型糖尿病腎病患者經口服吡咯列酮聯閤瑞格列奈治療後血糖、糖化血紅蛋白、尿白蛋白與尿肌酐比值等較前均有顯著降低(均P＜0.01),上述指標與對照組治療後同期差異有統計學意義(P＜0.05).結論 吡咯列酮聯閤瑞格列奈應用是治療外源性胰島素抗體暘性的2型糖尿病腎病的有效方法.
목적 관찰필각렬동연합서격렬내치료외원성이도소항체양성적2형당뇨병신병적료효.방법 장44예외원성이도소항체양성적당뇨병신병환자분성치료조(22례)화대조조(22례),치료조정용이도소개위필각렬동15 mg,매천1차,서격렬내1 mg,매천3차,구복병축점조정제량,대조조이도소,공치료12주,치료전후측정혈당、혈지、당화혈홍단백등.결과 2형당뇨병신병환자경구복필각렬동연합서격렬내치료후혈당、당화혈홍단백、뇨백단백여뇨기항비치등교전균유현저강저(균P＜0.01),상술지표여대조조치료후동기차이유통계학의의(P＜0.05).결론 필각렬동연합서격렬내응용시치료외원성이도소항체양성적2형당뇨병신병적유효방법.
Objective To observe the efficacy of pioglitazone combined with repaglinide in the treatment of external insulin antibody (IAb)-positive patients with type 2 diabetic nephropathy.Methods 44 cases with IAb positive diabetes nephropathy were divided into the treatment group (22 cases) and control group (22 cases).The treatment group moved gradually insulin to pioglitazone 15 mg once daily add repaglinide 1 mg three times daily oral and gradually adjustment dose.The control group continued to use insulin treatment,a total of 12 weeks.Before and after treatment,blood sugar,blood fat,glycosylated hemoglobin,etc were detected.Results Mter treatment,the blood glucose,glycosylated hemoglobin,urine albumin and urine creatinine ratio of the treatment group were significantly decreased (all P ＜ 0.01),the above indicators had statistically significant differences compared with the control group at the same period (P ＜ 0.05).Conclusion Pioglitazone combined with repaglinide is an effective method for treatment of IAb positive type 2 diabetic nephropathy.
